GSK, Novartis, Oryzon, Cellzome and Epizyme to present at The Epigenetics Congress

We are pleased to inform you that Dr. Rab Prinjha, VP, Head of Epigenetics - GlaxoSmithKline will be presenting the key note address at the Epigenetics Discovery Congress in London on the 24th of September 2015.

Dr. Prinjha currently leads GSK's Epinova Epigenetics DPU and is co-chair of the GSK Biology Council. Prior to this he led the Target Progression department with responsibilities for target selection, validation and epigenetic compound characterisation along with coordinating academic collaborations. He joined Epinova from the II-virtual group which was responsible for implementing the externalisation and portfolio diversification strategy of the Therapy Area.

At the Epigenetics Discovery Congress, Dr. Prinjha will be speaking about Epigenetics therapies in the clinical phase with special focus on:
  • Drugging the epigenome, entering the clinical phase
  • BET bromodomain inhibitors and their emerging pharmacology
  • Novel probes and their pharmacology across the “bromonome”, the next best BETs

For more details, download agendaOther companies who have confirmed their participation are representing organizations like:

  • Cellzome
  • Oryzon
  • Epizyme
  • Novartis
  • Erasmus University Rotterdams
  • Active Motif
  • Cancer Research UK
  • Diagenode
  • The Babraham Institute
  • Cambridge Biomedical Centre
  • University of Oxford
  • Blizard Institute
  • Volition Rx
  • Celgene
  • Reaction Biology
  • Promega

If you would like to meet Dr. Prinjha and many other such epigenetic experts, sign up for the congress today.
We are currently providing an Early Registration discount of 15% on registration fees till 30th June 2015. Take advantage of the offer, register today with 'MnM-EDC-03' as your discount code.

I look forward to welcoming you at the congress.
Best regards,
MnM Conferences
P.S : Please forward this to any colleagues who you feel may be interested in the congress.